Geode Capital Management, LLC Puma Biotechnology, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 950,146 shares of PBYI stock, worth $2.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

950,146

Previous 452,971 109.76%

Holding current value

$2.4 Million

Previous $2.4 Million 29.04%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.92 - $5.83 $1.45 Million - $2.9 Million	497,175 Added 109.76%	950,146 $3.1 Million
Q1 2024 May 13, 2024	BUY	$4.29 - $7.4 $38,288 - $66,045	8,925 Added 2.01%	452,971 $2.4 Million
Q4 2023 Feb 13, 2024	BUY	$2.23 - $4.49 $41,324 - $83,204	18,531 Added 4.35%	444,046 $1.92 Million
Q3 2023 Nov 13, 2023	BUY	$2.63 - $4.09 $76,582 - $119,096	29,119 Added 7.35%	425,515 $1.12 Million
Q2 2023 Aug 11, 2023	BUY	$2.6 - $3.58 $12,412 - $17,090	4,774 Added 1.22%	396,396 $1.4 Million
Q1 2023 May 15, 2023	BUY	$2.21 - $4.82 $23,671 - $51,627	10,711 Added 2.81%	391,622 $1.21 Million
Q4 2022 Feb 13, 2023	BUY	$2.12 - $5.08 $13,239 - $31,724	6,245 Added 1.67%	380,911 $1.61 Million
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $10,385 - $17,568	4,575 Added 1.24%	374,666 $887,000
Q2 2022 Aug 12, 2022	SELL	$1.64 - $3.3 $376,089 - $756,765	-229,323 Reduced 38.26%	370,091 $1.05 Million
Q1 2022 May 13, 2022	SELL	$2.13 - $3.24 $80,680 - $122,724	-37,878 Reduced 5.94%	599,414 $1.73 Million
Q4 2021 Feb 11, 2022	BUY	$2.85 - $6.58 $85,901 - $198,327	30,141 Added 4.96%	637,292 $1.94 Million
Q3 2021 Nov 12, 2021	SELL	$6.63 - $9.39 $92,654 - $131,225	-13,975 Reduced 2.25%	607,151 $4.26 Million
Q2 2021 Aug 13, 2021	BUY	$8.98 - $11.6 $168,267 - $217,360	18,738 Added 3.11%	621,126 $5.7 Million
Q1 2021 May 12, 2021	BUY	$9.38 - $13.63 $713,339 - $1.04 Million	76,049 Added 14.45%	602,388 $5.86 Million
Q4 2020 Feb 12, 2021	SELL	$7.78 - $12.13 $89,827 - $140,052	-11,546 Reduced 2.15%	526,339 $5.4 Million
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $103,265 - $121,091	10,870 Added 2.06%	537,885 $5.43 Million
Q2 2020 Aug 13, 2020	BUY	$7.01 - $13.24 $382,591 - $722,612	54,578 Added 11.55%	527,015 $5.5 Million
Q1 2020 May 14, 2020	SELL	$6.28 - $14.57 $587,845 - $1.36 Million	-93,606 Reduced 16.54%	472,437 $3.99 Million
Q4 2019 Feb 13, 2020	BUY	$6.5 - $10.73 $1.06 Million - $1.75 Million	163,303 Added 40.55%	566,043 $4.95 Million
Q3 2019 Nov 12, 2019	BUY	$8.75 - $12.85 $71,120 - $104,444	8,128 Added 2.06%	402,740 $4.34 Million
Q2 2019 Aug 14, 2019	BUY	$12.3 - $35.76 $316,011 - $918,745	25,692 Added 6.96%	394,612 $5.02 Million
Q1 2019 May 14, 2019	BUY	$20.77 - $42.37 $686,469 - $1.4 Million	33,051 Added 9.84%	368,920 $14.3 Million
Q4 2018 Feb 13, 2019	BUY	$20.07 - $46.7 $237,628 - $552,928	11,840 Added 3.65%	335,869 $6.83 Million
Q3 2018 Nov 13, 2018	BUY	$41.2 - $59.85 $799,115 - $1.16 Million	19,396 Added 6.37%	324,029 $14.9 Million
Q2 2018 Aug 14, 2018	BUY	$48.3 - $68.25 $303,130 - $428,337	6,276 Added 2.1%	304,633 $18 Million
Q1 2018 May 15, 2018	BUY	$59.7 - $99.25 $457,660 - $760,850	7,666 Added 2.64%	298,357 $20.3 Million
Q4 2017 Feb 13, 2018	BUY	$93.85 - $132.45 $729,402 - $1.03 Million	7,772 Added 2.75%	290,691 $28.7 Million
Q3 2017 Nov 14, 2017	BUY	$72.0 - $119.75 $1.76 Million - $2.92 Million	24,379 Added 9.43%	282,919 $33.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	258,540	258,540 $22.6 Million

Others Institutions Holding PBYI

# of Institutions

Shares Held

30.5M

Call Options Held

73.5K

Put Options Held

18.5K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $115M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Puma Biotechnology, Inc. Transaction History